Table 1.
Patient baseline profile.
| Characteristics | All monoclonal antibody therapies n = 188 | Omalizumab n = 34 | Mepolizumab n = 96 | Reslizumab n = 38 | Benralizumab n = 20 | Comparison of the 4 treatment groups, p-value |
|---|---|---|---|---|---|---|
| Age, years, median (IQR) | 55 (46–67) | 45.5 (38–57) | 59 (50–69) | 51.5 (42–67) | 62.5 (52.5–75) | 0.000 |
| Women, n (%) | 146 (77.7) | 25 (73.5) | 68 (70.8) | 35 (92.1) | 14 (70.0) | 0.067 |
| BMI, kg/m2, median (IQR) | 28.1 (24.4–32.5) | 28.3 (24.0–31.2) | 29.0 (24.0–31.2) | 23.9 (21.8–28) | 30.7 (27.9–37.5) | 0.000 |
| Comorbidities, n (%) | ||||||
| Obesity | 71 (37.8) | 9 (13.0) | 43 (44.8) | 6 (15.8) | 11 (55.0) | 0.004 |
| Ex-smokers | 62 (33.0) | 11 (32.3) | 35 (36.5) | 9 (23.7) | 7 (35.0) | 0.563 |
| Nasal polyposis | 71 (37.8) | 9 (26.5) | 36 (37.9) | 19 (50.0) | 7 (35.0) | 0.231 |
| Rhinosinusitis | 116 (61.7) | 24 (70.6) | 58 (61.0) | 23 (60.5) | 9 (45.0) | 0.327 |
| Atopy | 99 (52.7) | 28 (82.3) | 40 (41.7) | 17 (44.7) | 10 (50.0) | 0.000 |
| COPD | 10 (5.3) | 0 (0.0) | 7 (7.4) | 2 (5.3) | 1 (5.0) | 0.444 |
| Gastroesophageal reflux | 56 (29.8) | 11 (32.3) | 32 (33.7) | 8 (21.0) | 4 (20.0) | 0.378 |
| Laboratory parameters | ||||||
| Historical maximum of eosinophils (cells/μL), median (IQR) | 800 (500–1,300) | 900 (500–1,300) | 800 (500–1,300) | 800 (500–1,400) | 650 (400–900) | 0.349 |
| Respiratory functional parameters | ||||||
| FEV 1, %, median (IQR) | 77 (63–88.2) | 74.5 (67–93.1) | 76 (60.5–87.5) | 76 (66–88) | 77 (56–90) | 0.829 |
| FeNO, ppb, median (IQR) | 40 (23–62) | 44.2 (27.5–67) | 29.7 (17.5–61) | 39.5 (24–77) | 43.4 (24–76) | 0.431 |
| Asthma control parameters | ||||||
| ACT, median (IQR) | 15 (11–18) | 12 (11.5–15.5) | 15 (10–18) | 16 (11–18) | 13.5 (11–17) | 0.450 |
| Exacerbations/year, median (IQR) | 2 (1–3) | 2.5 (1–3.5) | 2 (1–3) | 2 (1–4) | 1.5 (0–2.5) | 0.034 |
| Previous hospital admissions/year, median (IQR) | 1 (0–2) | 2 (1–3) | 1 (0–1) | 2 (1–2) | 1 (0.5–2) | 0.000 |
n, number of patients; BMI, body mass index; IQR, interquartile range; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second; FeNO, fractional exhaled nitric oxide; ACT, asthma control test.